No Data
No Data
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Kangbo Medical-B (02216.HK): Sun Jiaen has been appointed as the company secretary, legal process document agent and authorized representative.
On June 25, Gelonhui announced that He Yanqun had resigned as the company secretary, legal document agent, and authorized representative, effective from June 25, 2024. Sun Jiaen has been appointed as the new representative of Fangyuan to replace Ms. He as the company secretary, legal document agent, and authorized representative, effective from June 25, 2024.
Kunbo Medical-B (02216.HK) grants 797,000 reward shares
Gelonghui, May 30, 丨 Kunbo Medical-B (02216.HK) announced that on May 30, 2024, the company awarded 797,241 awards (the same as the number of relevant shares, and approximately 0.15% of the total number of shares issued on the date of this announcement) to 4 grantees in accordance with the terms of the restricted share unit plan. The purpose of awarding rewards is to reward the grantor's performance and contribution to the Group, to align the interests of the grantor with those of the Group through ownership of shares, dividends and other share distributions and/or share appreciation, and to encourage and retain the grantor to contribute to the Group's long-term growth and profits.
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
BRONCUS-B: Annual Report 2023
No Data
102768097 : how to do?